(3) in Lovo-DX Cells

Total Page:16

File Type:pdf, Size:1020Kb

(3) in Lovo-DX Cells ANTICANCER RESEARCH 33: 857-864 (2013) The Influence of Phenothiazine Derivatives on Intracellular Accumulation of Cationic Cyanine Dye DiOC6(3) in LoVo-DX Cells ANDRZEJ POŁA1, DANIELA MOSIĄDZ1, JOLANTA SACZKO2, TERESA MODRZYCKA1 and KRYSTYNA MICHALAK1 Departments of 1Biophysics and 2Medical Biochemistry, Wrocław Medical University, Wroclaw, Poland Abstract. Aim: This study aimed to evaluate the influence phenomenon of human cancer cells, which is manifested by of phenothiazine derivatives (PDs) on the intracellular transport of a broad array of chemical compounds out of accumulation of cyanine dye DiOC6(3) in doxorubicin- cells (6, 7). Among MDR transporters, the earliest discovered resistant LoVo-DX cell line, with overexpression of P- was P-gp (8), hence, the molecular mechanism of its action glycoprotein. Materials and Methods: In order to maintain is best-understood. Most researchers suggest that P-gp acts a high expression level of P-gp, the LoVo-DX cells were as a pump that removes cytotoxic drugs, as well as other grown in the presence of doxorubicin (100 ng/ml). The time- structurally- and functionally-unrelated compounds, trying to dependent fluorescence signal (T-DFS) of the intracellular penetrate the cancer cell interior (4, 9-16). It seems that the accumulation of DiOC6(3), in the presence of PDs, was then electrical charge of transported molecules plays an important recorded. The rate constants k1, k2, k3 and amplitudes of T- role in recognizing compounds as substrates for MDR DFS, describing the intracellular accumulation process, transporters. P-gp has very high affinity for organic cations, were determined based on the respective theoretical whereas ABCC1 substrates share the property of being equation. Results: The values of k1 and k2 were dependent amphiphilic organic anions and glutathione or glucuronate on the hydrophobicity (logP) of the PDs used as drug conjugates (17, 18). It was found that amphiphilic drugs (19) resistance modulators. A rise of k1 and k2 values was and anions (20, 21), as well as cations (22, 23), can be observed when the logP of PDs increased. Conclusion: We transported by ABCG2. suggest that the k1 and k2 rate constants could be regarded Higher intracellular accumulation of anticancer drugs was as useful parameters for assessment of PDs as well as of observed in cell lines with low P-gp expression, as compared other compounds of potential application as reversers of to their resistant counterparts with P-gp overexpression (11, multidrug resistance. 24). Similarly, a lower intracellular concentration of cationic cyanine dyes was observed in cancer cells with high Multidrug resistance (MDR) of cancer cells is a basic reason expression of this transporter (25-27). Spectral properties of for frequent failure of chemotherapy in cancer treatment. The cyanines are very useful to determine the kinetic parameters molecular mechanism of MDR is multifactorial (1-3) but the describing the process of intracellular dye accumulation. The classical MDR phenotype is associated with overexpression kinetic parameters may be estimated from the model proposed of multidrug transporters belonging to the superfamily of by Wadkins and Houghton (26), which was established on the ATP-binding cassette proteins (ABC proteins), in the plasma basis of analyses of time-dependent fluorescence signals (T- membrane of cancer cells (4, 5). From the superfamily of DFS) during intracellular accumulation of cyanine dye in ABC proteins, mainly P-glycoprotein (P-gp; ABCB1), cancer cells with different P-gp expression levels. ABCC1 and ABCG2 are responsible for the MDR Many different chemical compounds can reverse or modulate MDR in cancer cells (5, 28). A very important group of compounds which in in vitro experiments has been shown to be MDR-reversing agents, are phenothiazine Correspondence to: Andrzej Poła, Department of Biophysics, derivatives (PDs). Phenothiazines are used in the treatment Wrocław Medical University, ul. Chałubińskiego 9, 50-368 Wrocław, Poland. E-mail: [email protected] of psychiatric disorders, and PDs are well-known substrates of P-gp (29-32). Key Words: LoVo, LoVo/DX, cyanine dyes, intracellular In the present article, we examined the influence of PDs, accumulation, phenothiazines. belonging to the perazine and promazine group, on the 0250-7005/2013 $2.00+.40 857 ANTICANCER RESEARCH 33: 857-864 (2013) intracellular accumulation of cationic carbocyanine dye Table I. Chemical structures of cyanine dye DiOC6(3) and phenothiazine derivatives from the promazine and perazine groups, and [DiOC6(3)] in colonic cancer cells with P-gp overexpression. Since both DiOC (3) and PDs are P-gp substrates, we assumed calculated values of logP for these compounds. *Calculated using the 6 software: SPARTAN ’08. that the presence of PDs in the cell suspension might affect the process of cyanine dye intracellular accumulation and, in consequence, changes in kinetic parameters describing this process should be detected. In the interpretation the results of our experiments a potential influence of ABCC1 and ABCG2 on intracellular accumulation of DiOC6(3) was excluded. The cationic dye used in our study was not a substrate in the case of ABCC1 protein. On the other hand, the expression ABCG2 protein was at the same level for both the LoVo and the LoVo-DX cell lines, what was confirmed in our laboratory (33). Materials and Methods Reagents. Promazine, chlorpromazine, trifluopromazine, prochlorpromazine, dimethyl sulfoxide (DMSO), DiOC6(3), dioxane, chloroform, butanol, acetone, ethanol, methanol, Dulbecco’s modified Eagle’s medium F12 Ham, cell dissociation solution non-enzymatic, doxorubicin hydrochloride, antibiotic antimycotic solution and fluorescein 5(6)-isothiocyanate (FITC) were purchased from Sigma, Poznań, Poland. Fetal bovine serum (FBS) was purchased from Gibco, Warsaw, Poland, L(+)-glutamine from BDH Prolabo, Wrocław, Poland and trifluoperazine from ICN Biomedicals Inc., Gdańsk, Poland. Perazine was supplied by FSP Galena, Wrocław, Poland. The antibody for P-gp was purchased from Santa Crus Biotechnology, Dallas, Texas, USA. Stock solutions of PDs (5 mM) and DiOC6(3) (400 μM) were prepared in DMSO. The chemical structure, kind of substituent at position 2 of the phenothiazine ring and calculated values of partition co-efficient (logP) for PDs used in these studies, are presented in Table I. Intracellular dye accumulation. The emission intensity of T-DFS Cell preparation. Doxorubicin-sensitive LoVo and doxorubicin- during intracellular accumulation of the dye was monitored at resistant LoVo-DX cells were obtained from Institute of λem=509 nm with excitation wavelength λex=482 nm. Fluorescence Immunology and Experimental Therapy (Polish Academy of measurements were carried-out with a Perkin-Elmer LS-50B Sciences, Wroclaw, Poland). Both cell lines were grown in spectrofluorimeter. A quartz cuvette, containing DiOC6(3) solution Dulbecco’s medium, supplemented with 10% FBS, L-glutamine and in cell medium (without FBS, glutamine, antibiotics) was placed in antibiotic solution. In order to maintain a high level expression of P- the spectrofluorimeter and then an appropriate volume of cell gp, the LoVo-DX cells were grown in the presence of doxorubicin suspension was added (sample was continuously stirred). The final (100 ng/ml). Cells were cultured at 37˚C in a humidified atmosphere concentration of DiOC6(3) was 0.4 μM and the cell density was 5 3 of 5% CO2. In log-phase growth, they were removed from the flask 2.5×10 cells/cm . To measure the kinetics of dye accumulation in surface with non-enzymatic cell dissociation solution. The density the presence of PD, an appropriate amount of PD in solution was of cells in suspension was determined using a Bürker mixed with the dye solution and then the cell suspension was added. haemocytometer and was usually about 106/cm3. The final concentration of PDs was 15 μM. Determination of P-gp expression by immunofluorescence. Cells in Mathematical analysis. The mathematical analysis of the intracellular growth medium were plated on cover glasses and were grown for accumulation of carbocyanine dyes was given by Wadkins and one or two days. They were fixed in 4% formalin buffer and washed Houghton (26). In our study, an equation (Eqtn 1) was applied to with PBS. The intracellular localization of P-gp was determined with estimate parameters characterizing dye accumulation in cells. The antibody detector labeled with FITC. Samples were attached to observed fluorescence intensity F(t) (T-DFS) for cyanine dye in the microscope slides using fluorescence mounting medium. form of monomers during its accumulation in cancer cells is given by: Fluorescence was monitored using a confocal scanning laser microscope (Carl Zeiss GmbH, Jena, Germany) with excitation wavelength λex of 470±20 nm and fluorescence emission recorded at λem=525±20 nm. (Eqtn 1) 858 Poła et al: Effect of PDs on DiOC6(3) Uptake in LoVo-DX Cells Results Confocal microscopy studies. Using confocal microscopy, we determined the expression of transporting membrane protein, P-gp, in both cell lines. We observed a significantly higher expression of P-gp in plasma and mitochondrial membranes of LoVo-DX cells, as compared to LoVo cells (Figure 1). Intracellular accumulation of DiOC6(3) in LoVo-DX and LoVo cells determined by fluorescence spectroscopy. The changes of T-DFS during intracellular accumulation of 5 3 DiOC6(3) for both cell lines (2.5×10 /cm ) are shown in Figure 2. The estimated value of rate constants k1 and k2 were higher for LoVo cells than for LoVo-DX cells. Like the rate constants the amplitudes A1 and A2 were also higher for LoVo cells (Table II). The solid lines in Figure 2 represent the theoretically calculated curves obtained by fitting of experimental data to Equation 1. Accumulation of DiOC6(3) in LoVo-DX cells in the presence of PDs determined by fluorescence spectroscopy. The addition of a given PD to the DiOC6(3) buffer solution (without the cells) caused a slight (less than 1%) decrease in the amplitude of T-DFS for the dye monomer (data not shown).
Recommended publications
  • Centre for Reviews and Dissemination
    Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta- analysis Leucht S, Corves C, D Arbter, Engel R R, Li C, Davis J M CRD summary The authors concluded that amisulpride, clozapine, olanzapine and risperidone can be effective in treating schizophrenia patients. Second-generation antipsychotic drugs can also result in fewer extrapyramidal side effects, but can induce weight gain. The authors' conclusions reflected the evidence presented, but some potential methodological flaws in the review process meant that the extent to which those conclusions were reliable was unclear. Authors' objectives To compare the effects of first and second-generation antipsychotic drugs in schizophrenia patients. Searching The search for eligible studies was started in 2005, including MEDLINE to October 2006, Cochrane Schizophrenia Group's Specialised Register and the US Food and Drugs Administration website. Search terms were reported and there were no language restrictions. Previous reviews were searched for additional relevant studies. Study selection Randomised controlled trials (RCTs) of oral second-generation antipsychotic drugs (amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone and zotepine) compared with first-generation drugs in patients with schizophrenia or related disorders (schizoaffective, schizophreniform or delusional disorders) irrespective of diagnostic criteria were eligible for inclusion in the review. The optimum doses of second-generation drugs were selected
    [Show full text]
  • Pharmacotherapy, Drug-Drug Interactions and Potentially
    medRxiv preprint doi: https://doi.org/10.1101/2021.03.31.21254518; this version posted April 6, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Pharmacotherapy, drug-drug interactions and potentially inappropriate medication in depressive disorders Jan Wolff1,2,3, Pamela Reißner4, Gudrun Hefner5, Claus Normann2, Klaus Kaier6, Harald Binder6, Christoph Hiemke7, Sermin Toto8, Katharina Domschke2, Michael Marschollek1, Ansgar Klimke4,9 1 Peter L. Reichertz Institute for Medical Informatics of TU Braunschweig and Hannover Medical School, Germany. 2 Department of Psychiatry and Psychotherapy, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany. 3 Evangelical Foundation NeuerKerode, Germany. 4 Vitos Hochtaunus, Friedrichsdorf, Germany. 5 Vitos Clinic for Forensic Psychiatry, Eltville, Germany 6 Institute of Medical Biometry and Statistics, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Germany. 7 Department of Psychiatry and Psychotherapy, University Medical Center Mainz, Germany. 8 Department of Psychiatry, Social Psychiatry and Psychotherapy, Hannover Medical School, Germany. 9 Heinrich-Heine-University Düsseldorf, Germany. ___ Correspondence Dr. Jan Wolff, Peter L. Reichertz Institute for Medical Informatics of TU Braunschweig and Hannover Medical School, Hannover, Germany. Address: Karl- Wiechert-Allee 3, 30625 Hannover. Email: [email protected], wolff.jan@mh- hannover.de, ORCID: https://orcid.org/0000-0003-2750-0606 Key words (MeSH) Depression, Polypharmacy, Antidepressants, Hospitals, Drug Interactions, Psychiatry NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
    [Show full text]
  • The Effects of Antipsychotic Treatment on Metabolic Function: a Systematic Review and Network Meta-Analysis
    The effects of antipsychotic treatment on metabolic function: a systematic review and network meta-analysis Toby Pillinger, Robert McCutcheon, Luke Vano, Katherine Beck, Guy Hindley, Atheeshaan Arumuham, Yuya Mizuno, Sridhar Natesan, Orestis Efthimiou, Andrea Cipriani, Oliver Howes ****PROTOCOL**** Review questions 1. What is the magnitude of metabolic dysregulation (defined as alterations in fasting glucose, total cholesterol, low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol, and triglyceride levels) and alterations in body weight and body mass index associated with short-term (‘acute’) antipsychotic treatment in individuals with schizophrenia? 2. Does baseline physiology (e.g. body weight) and demographics (e.g. age) of patients predict magnitude of antipsychotic-associated metabolic dysregulation? 3. Are alterations in metabolic parameters over time associated with alterations in degree of psychopathology? 1 Searches We plan to search EMBASE, PsycINFO, and MEDLINE from inception using the following terms: 1 (Acepromazine or Acetophenazine or Amisulpride or Aripiprazole or Asenapine or Benperidol or Blonanserin or Bromperidol or Butaperazine or Carpipramine or Chlorproethazine or Chlorpromazine or Chlorprothixene or Clocapramine or Clopenthixol or Clopentixol or Clothiapine or Clotiapine or Clozapine or Cyamemazine or Cyamepromazine or Dixyrazine or Droperidol or Fluanisone or Flupehenazine or Flupenthixol or Flupentixol or Fluphenazine or Fluspirilen or Fluspirilene or Haloperidol or Iloperidone
    [Show full text]
  • Antipsychotics and the Risk of Sudden Cardiac Death
    ORIGINAL INVESTIGATION Antipsychotics and the Risk of Sudden Cardiac Death Sabine M. J. M. Straus, MD; Gyse`le S. Bleumink, MD; Jeanne P. Dieleman, PhD; Johan van der Lei, MD, PhD; Geert W. ‘t Jong, PhD; J. Herre Kingma, MD, PhD; Miriam C. J. M. Sturkenboom, PhD; Bruno H. C. Stricker, PhD Background: Antipsychotics have been associated with Results: The study population comprised 554 cases of prolongation of the corrected QT interval and sudden car- sudden cardiac death. Current use of antipsychotics was diac death. Only a few epidemiological studies have in- associated with a 3-fold increase in risk of sudden car- vestigated this association. We performed a case- diac death. The risk of sudden cardiac death was high- control study to investigate the association between use est among those using butyrophenone antipsychotics, of antipsychotics and sudden cardiac death in a well- those with a defined daily dose equivalent of more than defined community-dwelling population. 0.5 and short-term (Յ90 days) users. The association with current antipsychotic use was higher for witnessed cases Methods: We performed a population-based case-control (n=334) than for unwitnessed cases. study in the Integrated Primary Care Information (IPCI) project, a longitudinal observational database with com- Conclusions: Current use of antipsychotics in a gen- plete medical records from 150 general practitioners. All eral population is associated with an increased risk of sud- instances of death between January 1, 1995, and April 1, den cardiac death, even at a low dose and for indica- 2001, were reviewed. Sudden cardiac death was classified tions other than schizophrenia.
    [Show full text]
  • Antipsychotics
    Antipsychotics If you experience psychosis as part of an illness, you may be offered antipsychotic medication. Antipsychotics are generally used to treat psychosis, but are also used to treat bipolar disorder and depression. This factsheet explains more about antipsychotic medication. There are two types of antipsychotics – ‘first generation’ or ‘typical’ (older medications) and ‘second generation’ or ‘atypical’ (newer medications). Antipsychotics affect people differently. If you take antipsychotics then you may get side effects. It can take some time to find the right medication. If you are taking an antipsychotic which you feel is not working, or if the side effects are difficult to live with, then you should discuss this with your GP or psychiatrist. You should not stop taking antipsychotics suddenly. Your antipsychotics can interact with other medications. It is important that your doctor is aware of all the medicine you are taking. This factsheet covers: 1. What are antipsychotics? 2. Are there different types of antipsychotics? 3. Are there any side effects? 4. What if I want to stop taking antipsychotics? 5. Do antipsychotics affect other medication? 6. Does alcohol affect my antipsychotics? 7. Can I drive when taking antipsychotics? 8. What else should I consider before taking antipsychotics? Top 1. What are antipsychotics? Psychosis is a medical term. If you have psychosis, you might see or hear things (hallucinations), or have ideas or beliefs that are not shared by other people around you (delusions). Some people describe it as a ‘break from reality’. Doctors may also describe it as ‘psychotic symptoms’, a ‘psychotic episode’ or a ‘psychotic experience’.
    [Show full text]
  • Screening of 300 Drugs in Blood Utilizing Second Generation
    Forensic Screening of 300 Drugs in Blood Utilizing Exactive Plus High-Resolution Accurate Mass Spectrometer and ExactFinder Software Kristine Van Natta, Marta Kozak, Xiang He Forensic Toxicology use Only Drugs analyzed Compound Compound Compound Atazanavir Efavirenz Pyrilamine Chlorpropamide Haloperidol Tolbutamide 1-(3-Chlorophenyl)piperazine Des(2-hydroxyethyl)opipramol Pentazocine Atenolol EMDP Quinidine Chlorprothixene Hydrocodone Tramadol 10-hydroxycarbazepine Desalkylflurazepam Perimetazine Atropine Ephedrine Quinine Cilazapril Hydromorphone Trazodone 5-(p-Methylphenyl)-5-phenylhydantoin Desipramine Phenacetin Benperidol Escitalopram Quinupramine Cinchonine Hydroquinine Triazolam 6-Acetylcodeine Desmethylcitalopram Phenazone Benzoylecgonine Esmolol Ranitidine Cinnarizine Hydroxychloroquine Trifluoperazine Bepridil Estazolam Reserpine 6-Monoacetylmorphine Desmethylcitalopram Phencyclidine Cisapride HydroxyItraconazole Trifluperidol Betaxolol Ethyl Loflazepate Risperidone 7(2,3dihydroxypropyl)Theophylline Desmethylclozapine Phenylbutazone Clenbuterol Hydroxyzine Triflupromazine Bezafibrate Ethylamphetamine Ritonavir 7-Aminoclonazepam Desmethyldoxepin Pholcodine Clobazam Ibogaine Trihexyphenidyl Biperiden Etifoxine Ropivacaine 7-Aminoflunitrazepam Desmethylmirtazapine Pimozide Clofibrate Imatinib Trimeprazine Bisoprolol Etodolac Rufinamide 9-hydroxy-risperidone Desmethylnefopam Pindolol Clomethiazole Imipramine Trimetazidine Bromazepam Felbamate Secobarbital Clomipramine Indalpine Trimethoprim Acepromazine Desmethyltramadol Pipamperone
    [Show full text]
  • (19) 11 Patent Number: 6165500
    USOO6165500A United States Patent (19) 11 Patent Number: 6,165,500 Cevc (45) Date of Patent: *Dec. 26, 2000 54 PREPARATION FOR THE APPLICATION OF WO 88/07362 10/1988 WIPO. AGENTS IN MINI-DROPLETS OTHER PUBLICATIONS 75 Inventor: Gregor Cevc, Heimstetten, Germany V.M. Knepp et al., “Controlled Drug Release from a Novel Liposomal Delivery System. II. Transdermal Delivery Char 73 Assignee: Idea AG, Munich, Germany acteristics” on Journal of Controlled Release 12(1990) Mar., No. 1, Amsterdam, NL, pp. 25–30. (Exhibit A). * Notice: This patent issued on a continued pros- C.E. Price, “A Review of the Factors Influencing the Pen ecution application filed under 37 CFR etration of Pesticides Through Plant Leaves” on I.C.I. Ltd., 1.53(d), and is subject to the twenty year Plant Protection Division, Jealott's Hill Research Station, patent term provisions of 35 U.S.C. Bracknell, Berkshire RG12 6EY, U.K., pp. 237-252. 154(a)(2). (Exhibit B). K. Karzel and R.K. Liedtke, “Mechanismen Transkutaner This patent is Subject to a terminal dis- Resorption” on Grandlagen/Basics, pp. 1487–1491. (Exhibit claimer. C). Michael Mezei, “Liposomes as a Skin Drug Delivery Sys 21 Appl. No.: 07/844,664 tem” 1985 Elsevier Science Publishers B.V. (Biomedical Division), pp 345-358. (Exhibit E). 22 Filed: Apr. 8, 1992 Adrienn Gesztes and Michael Mazei, “Topical Anesthesia of 30 Foreign Application Priority Data the Skin by Liposome-Encapsulated Tetracaine” on Anesth Analg 1988; 67: pp 1079–81. (Exhibit F). Aug. 24, 1990 DE) Germany ............................... 40 26834 Harish M. Patel, "Liposomes as a Controlled-Release Sys Aug.
    [Show full text]
  • Drug and Medication Classification Schedule
    KENTUCKY HORSE RACING COMMISSION UNIFORM DRUG, MEDICATION, AND SUBSTANCE CLASSIFICATION SCHEDULE KHRC 8-020-1 (11/2018) Class A drugs, medications, and substances are those (1) that have the highest potential to influence performance in the equine athlete, regardless of their approval by the United States Food and Drug Administration, or (2) that lack approval by the United States Food and Drug Administration but have pharmacologic effects similar to certain Class B drugs, medications, or substances that are approved by the United States Food and Drug Administration. Acecarbromal Bolasterone Cimaterol Divalproex Fluanisone Acetophenazine Boldione Citalopram Dixyrazine Fludiazepam Adinazolam Brimondine Cllibucaine Donepezil Flunitrazepam Alcuronium Bromazepam Clobazam Dopamine Fluopromazine Alfentanil Bromfenac Clocapramine Doxacurium Fluoresone Almotriptan Bromisovalum Clomethiazole Doxapram Fluoxetine Alphaprodine Bromocriptine Clomipramine Doxazosin Flupenthixol Alpidem Bromperidol Clonazepam Doxefazepam Flupirtine Alprazolam Brotizolam Clorazepate Doxepin Flurazepam Alprenolol Bufexamac Clormecaine Droperidol Fluspirilene Althesin Bupivacaine Clostebol Duloxetine Flutoprazepam Aminorex Buprenorphine Clothiapine Eletriptan Fluvoxamine Amisulpride Buspirone Clotiazepam Enalapril Formebolone Amitriptyline Bupropion Cloxazolam Enciprazine Fosinopril Amobarbital Butabartital Clozapine Endorphins Furzabol Amoxapine Butacaine Cobratoxin Enkephalins Galantamine Amperozide Butalbital Cocaine Ephedrine Gallamine Amphetamine Butanilicaine Codeine
    [Show full text]
  • Lamotrigine, Quetiapine and Aripiprazole-Induced Neuroleptic
    Szota et al. BMC Psychiatry (2020) 20:179 https://doi.org/10.1186/s12888-020-02597-x CASE REPORT Open Access Lamotrigine, quetiapine and aripiprazole- induced neuroleptic malignant syndrome in a patient with renal failure caused by lithium: a case report Anna Maria Szota* , Izabela Radajewska, Przemysław Grudzka and Aleksander Araszkiewicz Abstract Background: Neuroleptic malignant syndrome (NMS) may be induced by atypical antipsychotic drugs (AAPDs) such as aripiprazole, olanzapine, risperidone and quetiapine, either as a single treatment or in combination with other drugs. A case of NMS following the administration of lamotrigine, aripiprazole and quetiapine in a patient with bipolar disorder, and with renal failure caused by toxic lithium levels has not been reported. Case presentation: A 51-year-old female patient with a 27-year history of bipolar disorder, being treated with lithium, fluoxetine, olanzapine, gabapentine, perazine and biperiden, was admitted to the hospital due to depressed mood and delusions. A urinary tract infection was diagnosed and antibiotic therapy was initiated. After 5 days of treatment her physical state deteriorated and she developed a fever of 38.4 °C. Her laboratory results revealed a toxic level of lithium (2.34 mmol/l). Acute renal failure was diagnosed and the lithium was withdrawn. After stabilization of her condition, and despite her antipsychotic treatment, further intensification of delusions and depressed mood were observed. All drugs being taken by the patient were withdrawn and lamotrigine and aripiprazole were initiated. Due to the insufficient effectiveness of aripiprazole treatment and because of problems with sleep, quetiapine was added, however further treatment with this drug combination and an increase of quetiapine to 400 mg/d eventually caused NMS.
    [Show full text]
  • The Effect of the Process Variables on the HPLC Separation of Tricyclic Neuroleptics on a Calixarene-Bonded Stationary Phase
    ORIGINAL ARTICLES Institute of Pharmacy, Pharmaceutical/Medicinal Chemistry, Ernst-Moritz-Arndt-University Greifswald, Greifswald, Germany The effect of the process variables on the HPLC separation of tricyclic neuroleptics on a calixarene-bonded stationary phase H. Hashem, Th. Jira Received March 15, 2004, accepted May 25, 2004 Priv.-Doz. Dr. Thomas Jira, Ernst-Moritz-Arndt-University Greifswald, Institute of Pharmacy, Pharmaceu- tical/Medicinal Chemistry, F.-L.-Jahnstr. 17, D-17487 Greifswald, Germany [email protected] Pharmazie 60: 186–192 (2005) The chromatographic behavior of a new HPLC-stationary phase with supramolecular selectors on the basis of calixarenes is described for the separation of nine tricyclic neuroleptics. The effects of differ- ent chromatographic conditions (buffer system, pH-value, type and content of organic modifier, injec- tion volume) on the separation of the analytes were studied. Additionally, the effect of structural differ- ences of the neuroleptic analytes was studied. The chemical structure and pKa of the neuroleptics highly influenced their separation on the calix[8]arene phase. The separation of all analytes on the investigated calixarene-bonded stationary phase was possible with a mobile phase of acetonitrile with 30 mM ammonium acetate buffer (pH 3.5) 30 : 70(v/v) using 1 ml/min flow rate. 1. Introduction Neuroleptics which are widely used for the treatment of CH3 psychological problems are basic compounds, mainly thiox- CH3 anthene and phenothiazine derivatives. Many papers de- N N CH3 scribe the separation of this pharmacological group of ana- N N CH3 lytes on the usual RP-stationary phases (Goldstein and Van S CH3 S O Vunakis 1981; Kountourellis and Markopoulou 1991; Trac- CH3 qui et al.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,197,764 B1 Bradley Et Al
    USOO6197764B1 (12) United States Patent (10) Patent No.: US 6,197,764 B1 Bradley et al. (45) Date of Patent: *Mar. 6, 2001 (54) CLOZAPINE COMPOSITIONS AND USES FOREIGN PATENT DOCUMENTS THEREOF 0599 576A1 1/1994 (EP). (75) Inventors: Matthews O. Bradley, Laytonsville, 693498 1/1996 (EP). MD (US); Victor E. Shashoua, 61204136 11/1984 (JP). Belmont, MA (US); Charles S. 06-072868 3/1994 (JP). Swindell, Merion; Nigel L. Webb, 6072868 3/1994 (JP). Bryn Mawr, both of PA (US) 7082146 3/1996 (JP). 8151334 6/1996 (JP). (73) Assignee: Protarga, Inc., Conshohocken, PA (US) 9030963 2/1997 (JP). (*) Notice: Subject to any disclaimer, the term of this WO 89/07938 9/1989 (WO). patent is extended or adjusted under 35 WO 96/04001 2/1996 (WO). U.S.C. 154(b) by 0 days. WO 96/22303 7/1996 (WO). WO 96/27380 9/1996 (WO). This patent is Subject to a terminal dis WO98/17325 4/1998 (WO). claimer. OTHER PUBLICATIONS (21) Appl. No.: 08/978,541 (22) Filed: Nov. 26, 1997 Bourat, et al., "Long Chain Esters of Pipotiazine as Lon g-Acting Psychotropic Pro-Drug, Med. Chem. Proc. Int. (51) Int. Cl. .............................................. A61K 31/00 Symp. 5th (1976) pp. 105-114. (52) U.S. Cl. ........................... 514/218; 514/219; 514/220 Lohr, et al., “Neuroleptic-Induced Movement Disorders . (58) Field of Search ..................................... 514/218, 219, ..", Psychiatry, vol. 3, (1989). 514/220 Makino, et al., Chemical Abstracts, vol. 106, No. 12, (56) References Cited (90.177x) issued Mar. 23, 1987, “Pharmaceuticals Permeable to Blood-Brain Barrier'.
    [Show full text]
  • Cyclic Antidepressant Drugs SI Conversion: [AUQ: Dr
    834 II: THERAPEUTIC DRUGS 127. Spiker DG, Pugh DD. Combining tricyclic and monoamine oxidase inhibi- 145. Chambost M, Liron L, Peillon D, et al. [Serotonin syndrome during fluoxetine tor antidepressants. Arch Gen Psychiatry 1976;33(7):828–830. poisoning in a patient taking moclobemide.] Can J Anaesth 2000;47(3):246– 128. Peebles-Brown AE. Hyperpyrexia following psychotropic drug overdose. 250. Anaesthesia 1985;40(11):1097–1099. 146. Myrenfors PG, Eriksson T, Sandsted CS, et al. Moclobemide overdose. J 129. Tuck JR, Punell G. Uptake of (3H)5-hydroxytryptamine and (3H)noradrenaline Intern Med 1993;233(2):113–115. by slices of rat brain incubated in plasma from patients treated with chlorimi- 147. Pounder DJ, Jones GR. Post-mortem drug redistribution––a toxicological pramine, imipramine or amitriptyline. J Pharm Pharmacol 1973;25(7):573–574. nightmare. Forensic Sci Int 1990;45(3):253–263. 130. Gillman PK. Successful treatment of serotonin syndrome with chlorproma- 148. Lichtenwalner MR, Tully RG, Cohn RD, et al. Two fatalities involving zine. Med J Aust 1996;165(6):345–346. phenelzine. J Anal Toxicol 1995;19(4):265–266. 131. Graham PM. Successful treatment of the toxic serotonin syndrome with 149. Yonemitsu K, Pounder DJ. Postmortem changes in blood tranylcypromine chlorpromazine. Med J Aust 1997;166(3):166–167. concentration: competing redistribution and degradation effects. Forensic 132. Tackley RM, Tregaskis B. Fatal disseminated intravascular coagulation fol- Sci Int 1993;59(2):177–184. lowing a monoamine oxidase inhibitor/tricyclic interaction. Anaesthesia 150. Baselt RC, Shaskan E, Gross EM. Tranylcypromine concentrations and 1987;42(7):760–763.
    [Show full text]